Christiane Hampe, Ph.D., Senior Director of Research, will present preclinical data on Immusoft’s Immune System Programming Platform
SEATTLE–(BUSINESS WIRE)–Immusoft Corporation, a cell therapy company dedicated to improving the lives of patients with rare diseases, today announced that it will present at the upcoming WORLDSymposium 2022 Conference, held in San Diego, February 7-11, 2022. WORLDSymposium is the largest international gathering of lysosomal disease researchers.
Details of the presentation are as follows:
Presentation Title: Iduronidase-transposed human B lymphocytes correct enzyme deficiency and glycosaminoglycan storage disease in immunodeficient mucopolysaccharidosis type I mice
Date/Time: Thursday, February 10, 2022, 1 pm PT (4 pm ET)
Presenter: Christiane Hampe, Ph.D., Senior Director of Research, Immusoft
Immusoft is developing a new modality of gene delivery that holds the promise of being both durable and re-dosable. The company’s lead investigational drug candidate ISP-001, is a first-in-class investigational treatment for Hurler syndrome, the most severe form of mucopolysaccharidosis type I (MPS I), a rare lysosomal storage disease. There is a significant unmet need for new therapies with improved efficacy and convenience in MPS I, where the current standard of care is enzyme replacement therapy (ERT).
Additional information regarding the WORLDSymposium presentation can be found at: https://worldsymposia.org/.
Immusoft is a cell therapy company focused on developing novel therapies for rare diseases using a sustained delivery of protein therapeutics from a patient’s own cells. The company is developing a technology platform called Immune System Programming (ISP™), which modifies a patient’s B cells and instructs the cells to produce gene-encoded medicines. The B cells that are reprogrammed using ISP become miniature drug factories that are expected to survive in patients for many years. The company is based in Seattle, WA. For more information, visit www.immusoft.com.
MediaKimberly HaKKH Advisors917email@example.com
Funding will support the first-ever engineered B cell clinical program The company has received FDA Orphan Drug Designation and Rare Pediatric Disease Designation for ISP-001 in MPS I (Mucopolysaccharidosis type I) San Francisco, CA – (BUSINESS WIRE) – January 26, 2023 — Immusoft of CA,…
Immusoft makes history with the first engineered B cell investigational therapy cleared for human trials Immusoft seeks to improve the treatment of MPS I, a rare childhood disease, through the use of its Immune System Programming (ISP™) approach that utilizes B cells as re-dosable biofactories…